Assessment of the Role of the Anti-Mullerian Hormone, Luteinizing Hormone/Follicle Stimulating Hormone Ratio in the Diagnosis of Polycystic Ovary Syndrome in Sudanese Women by Tola, Hafza et al.
 _______________________________________________________________________________________________________________________________ 
1244                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2018 Jul 20; 6(7):1244-1247. 
https://doi.org/10.3889/oamjms.2018.260 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
Assessment of the Role of the Anti-Mullerian Hormone, 
Luteinizing Hormone/Follicle Stimulating Hormone Ratio in the 
Diagnosis of Polycystic Ovary Syndrome in Sudanese Women 
 
 
Hafza Tola
1
, Mohammed Abbas
2
, Elsir Abu Alhassan
3
, Nassr Eldin Shrif
1
, Mohammed Rida
3*
 
 
1
Faculty of Medical Laboratory Sciences, Alzaim Alazhari University, Sudan;  
2
Medical Laboratory Sciences Program, Allied 
Health Department, College of Health Sciences, University of Bahrain, Kingdom of Bahrain; 
3
Dr. Elsir Abu Alhassan Fertility 
Center, Khartoum, Sudan 
 
Citation: Tola H, Abbas M, Alhassan EA, Shrif NE, Rida 
M. Assessment of the Role of the Anti-Mullerian Hormone, 
Luteinizing Hormone/Follicle Stimulating Hormone Ratio 
in the Diagnosis of Polycystic Ovary Syndrome in 
Sudanese Women. Open Access Maced J Med Sci. 2018 
Jul 20; 6(7):1244-1247. 
https://doi.org/10.3889/oamjms.2018.260 
Keywords: Anti-Müllerian hormone; Follicle Stimulating 
Hormone; Luteinizing Hormone; Ovulation; Polycystic 
Ovary Syndrome; Sudanese women 
*Correspondence: Mohammed Rida. Dr Elsir Abu 
Alhassan Fertility Center, Khartoum, Sudan. E-mail: 
mohedalirida@gmail.com 
Received: 15-Mar-2018; Revised: 22-May-2018; 
Accepted: 25-May-2018; Online first: 17-Jul-2018  
Copyright: © 2018 Hafza Tola, Mohammed Abbas, Elsir 
Abu Alhassan, Nassr Eldin Shrif, Mohammed Rida. This is 
an open-access article distributed under the terms of the 
Creative Commons Attribution-NonCommercial 4.0 
International License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
Abstract 
BACKGROUND: The diagnosis of polycystic ovary syndrome (PCOS) is not an easy procedure, as the signs and 
symptoms are heterogeneous and of undefined aetiology.  
AIM: This study is aimed to evaluate serum anti-Mullerian hormone (AMH) level and luteinizing hormone (LH)/folic 
stimulating hormone (FSH) ratio in women with PCOS in Sudan and to assess the diagnostic efficiency for the 
diagnosis of PCOS. 
METHODS: In a case-control study, Serum AMH, LH, FSH was measured in the early follicular phase from 
Sudanese patients (N = 230) with PCOS and100 controls. The LH/FSH ratio was calculated, and its diagnostic 
power was evaluated by receiver operating characteristic curves.  
RESULTS: The means of serum AMH, serum LH level and LH/FSH ratio of the test, were significantly increased 
in the test group compared to the control group (P-value < 0.000). The AMH sensitivity, specificity, Positive 
Predictive Value (PPV) and Negative Predictive Value (NPV) were found to be 83%, 99%, 99%, and 72% 
respectively. Serum AMH was considered adequate measures for the diagnosis of PCOS; its level showed an 
area under the ROC curve of 0.98 (95% confidence, P-value < 0.000). The best compromise between 98% 
specificity and 90% sensitivity was obtained with a cut-off value of 3.3 ng/mL for PCOS diagnosis. There was no 
correlation between age, body mass index (BMI) and AMH level in the test group. 
CONCLUSIONS: The Serum AMH level and LH/FSH ratio were higher in patients than in control. However AMH 
level has better discriminative power and good diagnostic potency for the diagnosis of the PCOS among 
Sudanese women. 
 
 
 
 
Introduction 
 
Polycystic ovary syndrome (PCOS) is one of 
the most common female endocrine disorders that 
affects up to 10% of women worldwide. PCOS is 
accompanied by an imbalance of female sex 
hormones and increased androgen production leading 
to infrequent or prolonged menstrual periods, excess 
hair growth, acne and obesity [1]. The exact aetiology 
is not yet known. However many risk factors have 
been demonstrated such as genetic and epigenetic or 
environmental factor leading to intraovarian 
hyperandrogenism
 
[1]. Lack of ovulation in PCOS 
results in continuous high levels of estrogen and 
insufficient progesterone which lead to increased 
serum luteinizing hormone (LH) levels as well as 
changes in Anti-Mullerian Hormone (AMH) secretion. 
The higher the antral follicles count, the higher AMH 
levels, and women with PCOS typically have high 
numbers of antral follicles [2]. 
The diagnosis of PCOS is not easy as signs 
and symptoms are heterogeneous, the lack of well-
defined diagnostic criteria makes identification of this 
common disease confusing to many clinicians. The 
guideline made by the American Society of 
Reproductive Medicine (ASRM) and European 
Society for Human Reproduction Medicine (ESHR) 
delivered in 2003 (Rotterdam criteria) determined the 
diagnostic criteria for PCOS which include: irregular 
menstrual cycle, androgen excess symptoms, and 
ovary ultrasound. A diagnosis of PCOS requires the 
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presence of at least two of the three features after 
other androgen-excess disorders have been excluded 
[3].  
 There are a considerable number of reasons 
to believe that many women with PCOS have been 
missed diagnosed, because of the extensive 
heterogeneity in the clinical presentation of PCOS. 
Furthermore, with the rising epidemic of obesity, the 
prevalence of PCOS may increase, as obesity 
potentially worsens the endocrine and metabolic 
profile of PCOS [4]. To the best of our knowledge, this 
is the first study to assess the diagnostic efficiency of 
AMH level and LH/FSH ratio for the diagnosis of 
PCOS among Sudanese women.  
 
 
Material and Methods 
 
A total of 230 Sudanese women with PCOS 
diagnosed based on Rotterdam criteria were enrolled 
in this study. The control subjects were 100 women. 
The study was conducted at Dr Elsir Abu Alhassan 
Fertility Center, Khartoum, Sudan. Patients with a 
history of menstrual disturbances (hypothyroidism, 
congenital adrenal hyperplasia, Cushing's syndrome, 
hyperprolactinemia and hirsutism were excluded. Both 
groups were matched regarding age and BMI (BMI 
was given by = Weight(kg)/Height(m
2
)). The study 
was ethically approved by the ethical approval 
committee for medical research of Alzaim Alazhari 
University, and informed consent was collected before 
the beginning of the study. 
Blood sampling was performed in the early 
follicular phase, between day 2 and 5 after the last 
menstrual period both in PCOS patients and controls. 
Serum AMH levels were assessed by ELISA 
(Enzyme-Linked Immune Sorbet Assay) using 
BECKMAN COULTER Kit reagents. Serum LH and 
FSH were measured by mini VIDAS technology using 
BIOMERIEUX Kits reagent. The assay principle 
combines an enzyme immunoassay sandwich method 
with final fluorescent detection (ELFA). The method 
and the steps were followed as per company 
instructions. 
Data were analysed using the statistical 
package for social sciences (SPSS ver.17) (IBM 
Corp., Armonk, NY, USA). Comparison of means of 
AMH, FSH, LH hormone and LH/FSH ratio was 
conducted using a t-test. Associations between 
hormonal levels between control and study groups 
were measured by using the Chi-square test. 
Correlation between age, BMI and AMH were tested 
using person correlation. The test was considered 
significant when the P value is less than 0.05. 
Receiver operating characteristic (ROC) curves were 
constructed to examine the diagnostic test 
performance, i.e. its capacity to discriminate between 
controls and patients with PCOS. Sensitivity (y-axis) 
against [1-specificity (x-axis)] was plotted at each 
threshold level, and the area under the curve (AUC) 
was computed by the nonparametric Wilcoxon test. 
AUC represents the probability of correctly identifying 
controls and patients with PCOS. A value of 0.5 
means that the test result is no better than chance. 
 
 
Results 
 
The mean age of the test group and control 
group was (28.17 ± 5.12), (28.98 ± 5.52) respectively. 
BMI means of test and control was (25.72 ± 4.86), 
(25.16 ± 5.57) respectively. 
The mean of serum AMH, LH level and serum 
LH/FSH ratio of study subjects was significantly 
increased (P < 0.000) compared to the control group. 
There was the insignificant difference (P = 0.06) 
between the mean of serum FSH level of test group 
and control group (6.30 ± 3.64) compared to (7.23 ± 
5.24) respectively, as shown in Table1.  
Table 1: Comparison between mean of AMH, LH, FSH, LH/FSH 
ratio for test and control group 
Variable Test group 
(n = 230) 
Control group 
(n = 100) 
P-value 
AMH ng/ml 9.61 ± 5.82 
(3.79-15.43) 
1.80 ± 0.66 
(1.14-2.46) 
0.000 
LH mIU/L 10.55 ± 7.82 
(2.73-18.37) 
7.77 ± 6.79 
(0.98-14.56) 
0.000 
FSH mIU/L 
 
6.30 ± 3.64 
(2.66-9.94) 
7.23 ± 5.24 
(1.99-12.47) 
0.06 
LH/FSH ratio 1.80 ± 1.16 1.12 ± 1.22 0.000 
 
The table shows the mean±standard deviation, range in brackets (Min-Max) and p-value.  
A t-test was used for comparison; P value less than 0.05 considered significant. 
 
Table 2 showed the diagnostic power of AMH 
about sensitivity and specificity when 4.0 ng/ml was 
used as cut off point. The sensitivity, specificity, 
Positive Predictive Value (PPV) and Negative 
Predictive Value (NPV) were observed at 83%, 99%, 
99% and 72% respectively. The diagnostic power of 
the LH/FSH ratio about sensitivity and specificity when 
1:1 was used as cut off point were observed at 72%, 
76%, 84% and 62% respectively. 
Table 2: Shows the sensitivity, specificity, Positive Predictive 
Value (PPV) and Negative Predictive Value (NPV) of AMH and 
LH/FSH ratio to diagnose of PCOS 
 AMH LH/FSH 
Sensitivity 0.834 0.729 
Specificity 0.990 0.765 
Positive Predictive Value (PPV) 0.995 0.843 
Negative Predictive Value (NPV) 0.727 0.620 
Likelihood Ratio+ (LR+) 85.07 2.399 
Likelihood Ratio- (LR-) 5.967 2.571 
 
The AUC for the different hormone serum 
measurements is shown in Table 3. The AUC for AMH 
was 0.98 (95% confidence interval, P < 0.000), the 
compromise between specificity and sensitivity was 
(96% and 92%), (96% and 91%), (98% and 90%) was 
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obtained with threshold values of AMH 3.1, 3.2, 
3.3ng/ml respectively.  
Table 3: AUC of serum hormone concentrations for PCOS 
detection in women 
Hormone AUC (95% CI) ,  
P < 0.000 
Compromise between 
specificity and sensitivity 
Cut-off values 
AMH 0.98 96%, 92% 3.1 ng/ml 
  96% and 91% 3.2 ng/ml 
  98% and 90% 3.3 ng/ml 
LH/FSH ratio 0.74 76%, 72% 1:2 
 
The AUC for LH/FSH ratio was 0.74 (95% 
confidence interval P < 0.000) and the best 
compromise between specificity and sensitivity (76%, 
72%), was obtained with threshold values of LH/FSH 
ratio 1:1 as shown in Figure 1. 
 
Figure 1: ROC curves for the detection of PCOS AMH and LH/FSH 
ratio 
 
The results also showed that there was no 
correlation (P = 0.488) between age and AMH level in 
the test group (r = -0.046). Furthermore, there was no 
correlation (P = 0.492) between BMI and AMH level in 
the test group (r = 0.039), Figure 2 and 3 respectively. 
Discussion 
 
The present study is the first study to our 
knowledge to assess the role of the AMH level and 
LH/FSH ratio in the diagnosis of PCOS among 
Sudanese women.  
 
Figure 2: A scatter plot shows the correlation between the level of 
AMH and age in test (P-value = 0.488) 
 
The significant increase of AMH level in 
PCOS women compared to healthy women in this 
study is by the study by Bungum L et al., [5], in 
Sweden, they found a significant difference in mean 
AMH levels between the groups, the highest values 
being seen in the PCOS group. The result also agrees 
with results obtained by Pawelczak M et al., [6], they 
noticed a positive relationship between serum AMH 
and ovarian volume as well as peripheral follicular 
distribution in adolescents with PCOS. 
 
Figure 3: A scatter plot shows the correlation between the level of 
AMH and BMI in the test group (P-value = 0.492) 
 
In the present study, the level of the LH and 
LH/FSH ratio was significantly higher in patients than 
in control group. In contrast, there was no significant 
 Tola et al. Anti-Mullerian Hormone and Luteinizing Hormone/Follicle Stimulating Hormone Ratio in Polycystic Ovary Syndrome 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Jul 20; 6(7):1244-1247.                                                                                                                                                   1247 
 
difference level of FSH level. This may be due to 
increased androgen level in PCOS women, which 
leads to abnormalities of ovaries hormone that 
contributing to a relative suppression of FSH 
production. Our finding is in harmony with the results 
reported by Siebert TI et al., [7]. Sahmay S et al. also 
found the significant differences between the mean 
serum, FSH, LH and LH/FSH ratio of PCOS women 
and control groups in their study [8]. The specificity 
and NPV of AMH and LH/FSH ratio to diagnosis 
PCOS in the current study agrees with the results 
reported by Wetzka et al., [9], AMH showed 90% 
specificity with 71.2% sensitivity for the diagnosis of 
PCOS.  In the existing study Serum AMH, and 
LH/FSH ratio was considered adequate measures for 
the diagnosis of PCOS, they AURC levels showed 
0.98 and 0.74 (95% confidence, P=0.000) 
respectively. Similarly, Pigny P et al. conveyed that 
AMH measurement has been found to offer a 
relatively high specificity and sensitivity (92 and 67%, 
respectively) for PCOS [10]. In contrast to our result, 
recently Cengiz H et al. did not find AMH to be a 
reliable predictor for the presence of PCOS [11]. 
Furthermore, Li et a.,l reported that the serum AMH 
measurements presented a relatively poor diagnostic 
power, with a sensitivity of 61.7% and a specificity of 
70%. They attributed the causes to the lower 
prevalence of hyperandrogenism, obesity, and insulin 
resistance to racial differences in their study [12]. 
The cut-off value of AMH in this study (3.3 
ng/ml) is compatible with the previous result obtained 
by Sahmay S et al., [8] the large sample size was the 
common denominator between both studies, unlike 
cut-off values from other studies with small sample 
size [12] [13] [14]. The lack of correlation between 
age, BMI and AMH level observed in the current study 
is agreed again with result gotten by Sahmay S et al., 
they concluded there was no relation of age and BMI 
between PCOS and non-PCOS subjects in their study 
[8]. 
In conclusion, AMH was shown to be a useful 
parameter for the diagnosis of PCOS in this study. 
Our results suggested that AMH is primarily a marker 
of ovarian function and not associated with other 
organ pathologies such as adrenal gland dysfunction 
or metabolic disturbances. 
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